Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain LGND message board posts where the ticker symbol LGND has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest LGND SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-18-000168 Size: 6 KB
2018-12-12
8-K/A  Documents [Amend] Current report, item 9.01
Acc-no: 0000886163-18-000166 (34 Act)  Size: 19 KB
2018-12-06 001-33093
181220730
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001193125-18-325600 Size: 74 KB
2018-11-13
8-K  Documents Current report, item 8.01
Acc-no: 0000886163-18-000164 (34 Act)  Size: 20 KB
2018-11-13 001-33093
181175459
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000886163-18-000162 (34 Act)  Size: 6 MB
2018-11-08 001-33093
181169648
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0000886163-18-000159 (34 Act)  Size: 349 KB
2018-11-08 001-33093
181168265
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-18-000154 Size: 10 KB
2018-10-25
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-18-000152 Size: 10 KB
2018-10-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000886163-18-000150 Size: 6 KB
2018-10-12
8-K  Documents Current report, items 2.01 and 9.01
Acc-no: 0000886163-18-000148 (34 Act)  Size: 22 KB
2018-10-10 001-33093
181116097
More LGND SEC Filings


Related news from
Wed, 12 Dec 2018
08:28:50 +0000
Ligand Pharmaceuticals Inc. (LGND) Hedge Funds Are Snapping Up
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access […]
Tue, 11 Dec 2018
13:06:28 +0000
See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Inc NASDAQ NMS:LGND
Mon, 10 Dec 2018
15:00:00 +0000
Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application, indicating that Sermonix may proceed directly to a Phase 2 clinical study in the personalized medicine arena involving its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center study is expected to begin enrollment in early 2019 and will evaluate the activity of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation.
Sat, 08 Dec 2018
14:30:02 +0000
Why Is Ligand (LGND) Down 14.9% Since Last Earnings Report?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thu, 29 Nov 2018
13:50:00 +0000
Detailed Research: Economic Perspectives on American Tower Corporation (REIT), Ligand Pharmaceuticals, Teva Pharmaceutical Industries, Cummins, Alexander's, and Korea Electric Power — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Wed, 28 Nov 2018
19:35:22 +0000
Why Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Looks Like A Quality Company
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/why-ligand-pharmaceuticals-incorporated-nasdaqlgnd-looks-like-a-quality-company/">Read More...</a></div>
Wed, 21 Nov 2018
16:11:21 +0000
10 Triple-A Stocks to Buy for the Rest of 2018
Ligand Pharmaceuticals Inc (NASDAQ:LGND) is a unique type of biotech company. Instead of looking to take a drug or a family of drugs through the entire “lab-to-fab” product development process, LGND focuses on drug discovery, early stage drug development and product reformulation. This is the new age of biotech companies, and LGND is a prime example of how it should be done.
Wed, 21 Nov 2018
14:00:00 +0000
Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation
Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company located in Tempe, AZ. As part of the agreement, Ligand will fund and facilitate selected early antibody discovery activities and will in return receive an ownership position in iMBP. “Ligand is proud of its heritage of establishing strategic partnerships with innovative, emerging organizations with experienced management teams, and our agreement with iMetabolic Biopharma Corporation is another example of such an alliance,” said John Higgins, Chief Executive Officer of Ligand.
Thu, 15 Nov 2018
10:27:00 +0000
Edited Transcript of LGND earnings conference call or presentation 8-Nov-18 2:00pm GMT
Q3 2018 Ligand Pharmaceuticals Inc Earnings Call
Wed, 14 Nov 2018
15:00:00 +0000
Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver.
Tue, 13 Nov 2018
14:00:00 +0000
Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo
Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began in December of 2017. The research utilizes Vernalis' fragment and structure-based drug discovery platform for two undisclosed oncology targets.
Fri, 09 Nov 2018
12:41:12 +0000
Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.
Fri, 09 Nov 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and Intrexon
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace.
Thu, 08 Nov 2018
17:36:09 +0000
Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript
LGND earnings call for the period ending September 30, 2018.
Thu, 08 Nov 2018
14:30:02 +0000
Ligand Pharmaceuticals (LGND) Tops Q3 Earnings and Revenue Estimates
Ligand (LGND) delivered earnings and revenue surprises of 33.33% and 7.22%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Thu, 08 Nov 2018
13:26:20 +0000
Ligand: 3Q Earnings Snapshot
The San Diego-based company said it had net income of $2.80 per share. Earnings, adjusted for one-time gains and costs, came to $1.32 per share. The drugmaker posted revenue of $45.7 million in the period. ...
Thu, 08 Nov 2018
13:00:00 +0000
Ligand Reports Third Quarter 2018 Financial Results
Raises 2018 Financial Guidance



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is one of the brightest and most generous groups you will ever come across. While I firmly believe everyone has something to contribute to the collective wisdom, this is pretty much a left-brain group. Facts, evidence, and reasoned argument will earn you respect, even if some disagree with you." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards